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Since cardiorenal dysfunction is usually secondary to multiple factors acting in concert (and not only reduced cardiac output)
in the present paper we are going to focus on the interrelationship between heart failure with normal ejection fraction and the
development of cardiorenal syndrome. The coexistence of renal impairment in heart failure with preserved ejection fraction (CRS
type 2 and 4) is common especially in older females with hypertension and/or diabetes. It can be hypothesized that the incidence
of this disease association is growing, while clinical trials enrolling these patients are still lacking. The main mechanisms thought
to be involved in the pathophysiology of this condition are represented by the increase of intra-abdominal and central venous
pressure and the activation of the renin-angiotensin system. Differently from CRS in heart failure with reduced ejection fraction,
the involvement of the kidney may be under-diagnosed in patients with heart failure and preserved ejection fraction and the
optimal therapeutic strategy in this condition, though challenging, is far to be completely elucidated. Further studies are needed
to assess the best therapeutic regimen in patients with renal dysfunction (and worsening) and heart failure and preserved ejection
fraction.
1. Introduction
The cardiorenal syndrome (CRS) is a complex disease in
which heart and kidney are simultaneously affected and
their deleterious effects are reinforced in a feedback cycle,
with accelerated progression of renal and myocardial damage
[1–3].
The incidence of heart failure in the United States
approaches 10 per 1000 in those older than 65 years and
accounts for 1 million hospitalizations and 3 million office
visits annually [4]. During the natural history of cardiac
dysfunction, the critical importance of the cardiorenal inter-
action is emphasized by the fact that decreased renal function
predicts cardiovascular mortality and complicates heart
failure [5]. Baseline glomerular filtration rate (GFR) appears
to be a stronger predictor of mortality in patients with HF
than left ventricular ejection fraction or NYHA functional
class [6]. In the Candesartan in Heart Failure: Assessment
of Reduction in Mortality and Morbidity (CHARM), it was
observed that impaired renal function was independently
associated with heightened risk for death, cardiovascular
death, and hospitalization for heart failure in patients with
heart failure with both preserved as well as reduced LVEF
[7]. Patients with chronic renal insufficiency are at strikingly
higher risk for myocardial infarction, HF with systolic
dysfunction, HF with preserved left ventricular ejection
fraction, and death resulting from cardiac causes compared
with individuals with normal GFR [8]. Conversely, reversal
of renal dysfunction can improve cardiac function [9].
Hypertensive heart disease and HF with a normal ejection
fraction are common among individuals with advanced and
end-stage renal disease [10]. Renal disease patients with left
ventricular hypertrophy have accelerated rates of coronary
events and markers of uremia compared with those with
normal left ventricular mass, and a high proportion of
these individuals develop clinical HF [11]. It has recently
been observed [12] that the 50% of patients with preclin-
ical diastolic dysfunction had renal insufficiency that was
defined by calculated creation clearance of <60mL/min. In
these patients, proposed mechanisms for the progression of
2 International Journal of Nephrology
diastolic dysfunction include not only left ventricle stiffness,
but also vascular stiffening (systemic and pulmonary) and
volume expansion.
A more comprehensive characterization of the cardiore-
nal syndrome implicates the pathophysiologic disequilib-
rium between the heart and the kidney, in whichmalfunction
of one organ consequently promotes the impairment of
the other. Risk factors for its development include diabetes
mellitus, hypertension, and a history of congestive heart
failure or chronic renal failure.
Since cardiorenal dysfunction is usually secondary to
multiple factors acting in concert (and not only reduced
cardiac output) in the present paper we are going to
focus on the interrelationship between heart failure with
normal ejection fraction and the development of cardiorenal
syndrome.
Firstly, we are going to summarize the recent evidence
on heart failure with normal ejection fraction and on the
cardiorenal syndromes. Then the main pathophysiologic
mechanisms characterizing the cardiorenal syndrome devel-
oping in patients with heart failure and preserved ejection
fraction (HFPEF) are hypothesized and the challenges in
diagnosis and management of patients with cardiorenal
syndrome and HFPEF are discussed.
2. The Cardiorenal Syndrome
The term cardiorenal syndrome (CRS) has been variably
defined in the last decades without a well-accepted defini-
tion. Some investigators have suggested that this term should
be used to describe patients with coexisting severe cardiac
and renal dysfunction [13], while, more recently, a working
group of the US National Heart, Lung, and Blood Institute
used this term to describe the state in which advanced
congestive heart failure (CHF) becomes complicated by acute
impairment of kidney function [1–3]. According to these
investigators, renal responses are thought largely to be the
result of primary changes in cardiac function and CRS
could be therefore defined as “a state in which therapy to
relieve CHF symptoms is limited by further worsening renal
function.”
On the other hand, and from a broader point of view,
taking into account the dynamic and close interplay between
heart and kidney, the CRS has been recently viewed as “a
pathophysiologic disorder of the heart and kidneys whereby
acute or chronic dysfunction in one organ may induce acute
or chronic dysfunction in the other organ” [1–3, 14, 15].
As recently reported in the consensus conference of
the Acute Dialysis Quality Initiative [3], the cardiorenal
syndromes (CRS) were defined as “disorders of the heart and
kidney whereby acute or chronic dysfunction in one organ may
induce acute or chronic dysfunction of the other” and five
different types of cardiorenal syndrome are described [1–3].
According to this classification, the worsening of renal
function occurring in patients with heart failure and pre-
served ejection fraction may belong to CRS type 2. In this
syndrome, chronic heart disease and CKD frequently coexist
and it can be hardly distinguished which disease came first. In
other words, most often CRS type 2 cannot be distinguished
from CRS type 4, in which, among chronic heart disease the
following conditions should be considered: cardiomyopathy,
LV remodelling and dysfunction, diabetic cardiomyopathy
[16] congenital heart disease, but also diastolic dysfunction.
3. Heart Failure with Preserved
Ejection Fraction
The incidence of heart failure with preserved ejection
fraction (HFPEF) is reported to include about 50% of the
general heart failure population [17], while the prevalence of
HFPEF is still increasing over the last years when compared
to the prevalence of heart failure with reduced ejection
fraction (HFREF) [18]. Its prevalence is higher in the elderly
[19, 20] (especially in females); in a recent study of HFPEF,
all patients were aged >80 yrs, with a mean age of 87 [21].
Older age, hypertension, diabetes, obesity, and coronary
artery disease are risk factors for both HFPEF and HFREF.
[22]. In HFNEF, hypertension is a more common risk factor.
While in HFREF ischemic heart disease is the most common
etiology. In decompensated heart failure, 63% of patients
with systolic and 54% of patients with diastolic heart failure
have coronary artery disease [23].
As a result of modern evidence-based heart failure (HF)
therapy, the prognosis of patients with heart failure with
reduced left ventricular ejection fraction (HFREF) improved
progressively over the past 3 decades. Conversely, despite
frequent use of similar pharmacological agents, the prognosis
of patients with heart failure with normal left ventricular
ejection fraction (HFPEF) remained unaltered over the same
time period [24–27].
It has been reported that the risk of sudden cardiac
death is better correlated to left ventricular mass than
to the ejection fraction [28]. The left ventricular mass is
increased considerably in both HFPEF and HFREF; thus, the
risk assessment for sudden cardiac death based on ejection
fraction alone may not be appropriate [29].
Impaired left ventricular relaxation and increased passive
stiffness is the principal functional derangement in HFPEF
[30]. The pressure-volume relation during diastole shifts
upward and to the left; as a result there is a disproportionately
greater increase in diastolic pressure for any increase in
volume. In HFPEF, because of the disproportionate increase
in left ventricular diastolic pressure, there is an increase in
left atrial and pulmonary venous pressure that is associated
with symptoms and signs of pulmonary venous congestion
[31]. Postcapillary pulmonary hypertension resulting from
increased pulmonary venous pressure may precipitate right
heart failure. Left ventricular stroke volume and cardiac
output may also decline because of decreased end-diastolic
volume (preload dependent). Currently, left diastolic but
also nondiastolic abnormalities are discussed as possible
reasons for HFPEF. Nondiastolic abnormalities may include
an impairment of ventricular-vascular coupling [32], systolic
left ventricular (LV) dyssynchrony, systolic and diastolic
ventricular interactions (e.g., due to pericardial diseases, pul-
monary hypertension), or chronotropic incompetence [33]
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as possible contributors to the heart failure symptomatology
of these patients, while pathologies inducing changes in
chamber compliance lead to diastolic abnormalities of the
left ventricle [32].
3.1. Main Mechanisms for the Pathophysiology of CRS Type
2 Associated with Heart Failure and Normal Ejection
Fraction (Table 1)
3.1.1. Intra-Abdominal and Central Venous Pressure Elevation.
The Poiseuille law summarizes the relationship between
blood pressure, cardiac output, and systemic vascular resis-
tance. Cardiac flow is dependent on a sufficient pressure
gradient across the body’s capillary networks. HF (and
HF with preserved left ejection fraction) is marked by an
elevation in central venous pressure, which attenuates the
gradient across the glomerular capillary network. Indeed,
there is increasing evidence to support roles for elevated
renal venous pressure and intraabdominal pressure (IAP)
in the development of progressive renal dysfunction in
patients with HF. In one early experiment, Winton [34]
reported that urine formation by isolated canine kidney was
markedly reduced at renal venous pressures of 20mmHg
and abolished at pressures >25mmHg. Renal blood flow was
also diminished in proportion to the decrease in pressure
gradient across the afferent and efferent renal circulations,
probably caused by the increased efferent arterial pressure.
Rising renal venous pressure limited urine formation and
renal blood flow more than a reduction in arterial pressure.
Bradley and Bradley showed that abdominal compression to
produce IAP of 20mmHg in normal individuals markedly
reduced GFR and renal plasma flow. These relationships are
supported by modern in vivo animal models [35]. In a broad
spectrum of patients with cardiovascular disease, increased
central venous pressure was associated with impaired renal
function and independently associated with all-cause mor-
tality. Interestingly the slope between CVP and impaired
eGFR was steeper with relatively preserved cardiac function
[36].
In patients who underwent elective cardiac surgery, pre-
operative presence of high CVP was a strong predictor of the
occurrence of acute renal injury, independent of the presence
of low cardiac output [37].
In the recent years, there has also been increasing
recognition that oliguric acute renal dysfunction frequently
accompanies abdominal compartment syndrome in surgical
and trauma patients [38]. These changes are promptly
reversed by abdominal decompression andmay be associated
with subsequent polyuria.
The concept that venous congestion, not arterial blood
flow, is an important mediator of cardiorenal failure is
supported by the findings of the Evaluation Study of
Congestive Heart Failure and Pulmonary Artery Catheteri-
zation Effectiveness trial, in which only baseline right atrial
pressure, not arterial blood flow, correlated with baseline
serum creatinine [39].
Several mechanisms by which abdominal pressure might
contribute to CRS have been explored. Elevation of renal
Table 1: Mechanisms thought to be involved in the pathogenesis of
the cardiorenal syndrome in HFPEF patients.
Main mechanisms
(i) Intra-abdominal and central venous pressure elevation.
(ii) Activations of the renin-angiotensin systematic.
Other mechanisms
(i) Sympathetic overactivity.
(ii) Oxidative injury and endothelial dysfunction.
Precipitating factors
Disease conditions that is, Infections.
Drugs, that is, nonsteroidal inflammatory agents.
parenchymal pressure does not appear to have significant
effects on GFR or renal blood flow. This was shown in studies
of isolated porcine kidneys subjected to increasing amounts
of extrinsic pressure [35]. Conversely, elevated central and
renal venous pressures offer a stronger explanation for the
relationship between elevated IAP and renal dysfunction.
Elevating renal venous pressure by 30mmHg for 2 hours in
intact porcine kidneys resulted in a substantial reduction in
renal blood flow and GFR [35]. Furthermore, patients with
HF with impaired renal function at baseline or worsening
renal function during hospitalization have significantly ele-
vated central venous pressure relative to those with less renal
impairment [40]. In one study of intensive medical therapy
directed at volume reduction, hemodynamic profiles were
monitored in all patients with pulmonary artery catheters,
and only elevated central venous pressure correlated with
worsening versus preserved renal function [41]. The role
of elevated central and renal venous pressures is further
supported by the association of elevated jugular venous
pulsations on physical examination with higher baseline
serum creatinine and increased risk for hospitalization and
death caused by pump failure [42]. Finally, the associa-
tion of tricuspid regurgitation with renal dysfunction was
recently examined in 196 consecutive patients with HF. The
authors found that patients with at least moderate tricuspid
regurgitation by transthoracic echocardiography had lower
estimated GFR and that a linear relationship existed between
severity of tricuspid regurgitation and degree of GFR impair-
ment.
3.1.2. Renin-Angiotensin-Aldosterone Axis and Renal Dysfunc-
tion. The extreme sodium avidity and ventricular remod-
elling conferred by RAAS elaboration in HF are a mal-
adaptive response to altered hemodynamics, sympathetic
signaling, and progressive renal dysfunction.
On a therapeutic point of view, drugs that block the
renin-angiotensin system reduce the progression of both
heart and CKD. The optimal approach is the combination
of ACE-I and beta-blocker, the titration of dosage. The
addition of either an ARB or aldosterone antagonist is
depending on clinical conditions and patients characteristics.
Therapy of CHF and coexisting renal impairment is still not
evidence-based, since these patients are often excluded from
clinical trials. Since these patients are typically hypervolemic,
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more intensive diuretic therapy is needed. ACE-I and ARB
initiation may cause deterioration in renal function, which is
frequently transient and reversible. Anemia is often present
in patients with CRS type 2 and correction of anemia may
improve symptoms with no increase in survival [43].
Since the higher incidence of HF in the elderly, it
should be remembered that these patients show increased
susceptibility to renal dysfunction, impairment of sodium
and water excretion, and postural hypotension, and aggra-
vation of hypotension with the treatments (e.g., ACE-
inhibitors, b-blockers, nitrates, and hydralazine). Therapy
has to be individualized and consider aging-specific changes
in physiology, drug metabolism, drug pharmacokinetics
and tolerance, comorbidities, polypharmacy, and drug-drug
interactions.
3.1.3. Other Mechanisms
Sympathetic Overactivity. The adverse consequences of sym-
pathetic nervous system activity to the heart are well
known. Less well appreciated are the systemic effects of
renal sympathetic stimulation. There are now good data
to suggest that the renal sympathetic activation leads to
direct vascular effects. A recent pilot study of catheter-based
renal sympathetic denervation in patients with resistant
hypertension found significant improvements in GFR in
24% of patients undergoing the procedure [43]. In an HF
population, denervation could possibly affect renal function
and halt renal sympathetic nerve-mediated progression of
cardiac failure related to elaboration of catecholamines and
the RAAS. Further investigation into this exciting concept is
needed to determine whether it is clinically relevant.
3.1.4. Oxidative Injury and Endothelial Dysfunction. Neu-
rohormones are strong precipitants and mediators of an
oxidative injury cascade that leads to widespread endothelial
dysfunction, inflammation, and cell death in the CRS. In this
setting, AT-II seems to be particularly important, exerting
many deleterious effects through the activation of NADPH
oxidase and NADH oxidase. AT-II activates these 2 enzymes
within vascular smooth muscle cells, cardiac myocytes,
and renal tubular epithelial cells, generating superoxide, a
reactive oxygen species [44–46]. Reactive oxygen species
have many unfavourable effects in living tissues and likely
contribute to the processes of aging, inflammation, and
progressive organ dysfunction. Growing evidence supports
oxidative injury as a common link between progressive
cardiac and renal dysfunction. Because both primary cardiac
failure and primary renal failure lead to elaboration of the
RAAS, activation of oxidases by AT-II in one organ has the
potential to lead to progressive dysfunction in the secondary
organ through reactive oxygen species generation.
In summary, it can be hypothesized that, in patients
with HFPEF and cardiorenal syndrome, congestion [40,
41] leading to a reduction in the arteriovenous pressure
gradient across the kidney, as well as decrements in mean
arterial pressure and renal perfusion pressure, tends to
reduce glomerular filtration rate. Concomitantly, there is
the pathophysiologic activation of the renin-angiotensin-
aldosterone system (RAAS) and the sympathetic nervous
system (SNS) and the release of antidiuretic hormone,
endothelin, cytokines, and various other inflammatory and
vasoactive mediators that promote marked sodium and
water retention, volume overload and adverse cardiovascular
and renal remodeling. Under these conditions, another
important mechanism contributing to cardiorenal dysfunc-
tion during the progression of heart failure is the deficiency
in the production of compensatory natriuretic peptides
and/or resistance to its renal actions [47, 48].
3.2. Diagnostic and Therapeutic Interventions for Cardiorenal
Syndrome in HFPEF. So far there are no specific data on
the diagnostic interventions in patients with cardiorenal
syndrome and HFPEF.
Identifying the onset or progression of cardiorenal
syndrome is paramount to proper management and can
result in disease attenuation and prolonged survival both in
patients with preserved EF and in those with reduced EF [49].
Though current research has been focusing on identifying
markers that would permit an earlier or more accurate
diagnosis of cardiorenal syndrome, no factor is specific for
patients with HFPEF and CRS.
Neutrophil gelatinase-associated lipocalin (NGAL), a
recently discovered acute kidney injury biomarker, indicating
the accumulation of nephrotoxins and renal ischemia, typi-
cally precedes an elevation of creatinine by 48–72h. Cystatin
C, another acute kidney injury biomarker, has been suggested
to be a better and earlier predictor of glomerular function
than serum creatinine, as it is not affected by age, sex, race,
or muscle mass.
B-type natriuretic peptide (BNP) or N-terminal pro-
BNP (NT-pro-BNP) levels [50], which are general markers
of HF, can be evaluated when HF diagnosis is not certain.
Plasma levels of BNP or Ntpro- BNP increase with left
ventricular mass, wall stress, and filling pressures. To date,
baseline levels of NT-pro-BNP of 339 and 409 pg/mL have
been reported in patients with HF-PEF, higher than in
normal subjects but less elevated than usually observed in
decompensated HF with low EF. However the relationship
between BNP, renal function, and the severity of heart failure
is less clear [3], not only for diagnostic purposes, but also for
the management of therapy [51].
In regard to the potential diagnostic role(s) of imaging
techniques, there is no specific data for patients with CRS and
HFNEF. In the future, non-invasive techniques (such renal
vein blood flow assessment by Doppler technique) should be
refined to quantify renal blood flow. These data could be then
correlated with cardiac and renal biomarkers and to guide
ongoing therapy.
Despite the importance of HFNEF, the treatment of this
phenotype remains poorly understood [52]. Pharmacologic
treatment of HFNEF patients is aimed to decrease blood
pressure, promote regression of LV hypertrophy, prevent
tachycardia, treat symptoms of congestion, and maintain
atrial contraction as recommended by the ACC and the AHA
joint guidelines [53]. Optimizing hemodynamics is primarily
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achieved through reduction of cardiac preload and afterload.
ACE inhibitors and ARBs directly affect myocardial relax-
ation and compliance by blocking angiotensin II receptors,
thereby reducing interstitial collagen deposition and fibrosis
[54].
In many large, randomized, controlled clinical trials,
researchers have assessed the beneficial effects of ACE
inhibitors, b-block , and ARBs in HFREF patients, but
these effects have not been established in HFNEF patients.
Treatment recommendations are derived mainly from the
large evidence-based trials that existed for management of
HFREF [55] [Class I] or are based largely on the results
of small, nonrandomized studies, clinical experience, and
pathophysiologic reasoning [56] [Class III]. Recently, two
large-scale HFNEF trials have reported their disappointing
results: in the CHARMPreserved trial, the ARB candesartan
produced a modest reduction in hospitalizations for HF but
had no effect on mortality [57]; in PEP-CHF, the ACE-
inhibitor perindopril had similar effects.
No data are so far available specifically for patients with
CRS and HFPEF. It has been recently observed that decreased
eGFR was associated with an increased risk of early postmy-
ocardial infarction (MI) HF, the association being strongest
in patients with preserved ejection fraction, in whom it was
an important independent predictor of HF. Though renin-
angiotensin-aldosterone blockade is well documented to
reduce rates of late post-MI HF, particularly in patients with
depressed EF, it is not known if intensive reninangiotensin-
aldosterone blockade during the acute phase of MI affects
rates of early post-MI HF in patients with preserved EF and
impaired renal function [58].
It can be speculated that the therapeutic targets in
patients with CRS and HFPEF are represented mainly by
the reduction of cardiac filling pressure while maintaining
adequate volume status.
Restriction of sodium intake and the administration
of diuretics may be beneficial through reduction of LV
ventricular filling pressures. They are also useful in treating
hypertension, which is a common trigger for worsening
HFNEF. In the Hong Kong Diastolic Heart Failure, diuretics
alone appeared to be effective in reducing symptoms and
improving quality of life in HFNEF patients [59].
Diuretics should therefore be initiated at low dose and
uptitrated gradually to achieve adequate urine output. Once
volume status is normalized, maintenance often requires
chronic oral diuretic therapy with active fluid restriction
to forestall the tendency to volume overload created by
sustained neurohormonal activation and enhanced thirst.
Clinicians should bear in mind that if aggressive therapy is
employed, diuretic-induced hypovolemia can result in severe
renal injury or exacerbate any preexisting renal insufficiency.
Whenever diuretic resistance develops in these patients,
treatment does not differ from that of patients with CRS and
HFREF, including ultrafiltration, when needed [3, 5].
All the conditions able to aggravate renal injury (i.e.,
anemia and infections) should be timely identified and
properly treated and, similarly medications able to adversely
influence renal function (such as nonsteroidal inflammatory
agents) should be interrupted.
4. Conclusion
The coexistence of renal impairment in heart failure with
preserved ejection fraction (CRS type 2 and 4) is com-
mon especially in older females with hypertension and/or
diabetes. It can be hypothesized that the incidence of this
disease association is growing, while clinical trials enrolling
these patients are still lacking. Differently from CRS in
heart failure with reduced ejection fraction, the involvement
of the kidney may be under-diagnosed in patients with
heart failure and preserved ejection fraction and the optimal
therapeutic strategy in this condition, though challenging, is
far to be completely elucidated. Further studies are needed
to assess the best therapeutic regimen in patients with renal
dysfunction (and worsening) and heart failure and preserved
ejection fraction.
“The people who bind themselves to systems are
those who are unable to encompass the whole
truth and try to catch it by the tail; a system is
like the tail of truth, but the truth is like a lizard;
it leaves its tail in your fingers and runs away
knowing full well that it will grow a new one in
a twinkling.” (Ivan Turgenev to Leo Tolstoy)
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